BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wettstein L, Weil T, Conzelmann C, Müller JA, Groß R, Hirschenberger M, Seidel A, Klute S, Zech F, Prelli Bozzo C, Preising N, Fois G, Lochbaum R, Knaff PM, Mailänder V, Ständker L, Thal DR, Schumann C, Stenger S, Kleger A, Lochnit G, Mayer B, Ruiz-Blanco YB, Hoffmann M, Sparrer KMJ, Pöhlmann S, Sanchez-Garcia E, Kirchhoff F, Frick M, Münch J. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection. Nat Commun 2021;12:1726. [PMID: 33741941 DOI: 10.1038/s41467-021-21972-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Cariou M, Picard L, Guéguen L, Jacquet S, Cimarelli A, Fregoso OI, Molaro A, Navratil V, Etienne L. Distinct evolutionary trajectories of SARS-CoV-2-interacting proteins in bats and primates identify important host determinants of COVID-19. Proc Natl Acad Sci U S A 2022;119:e2206610119. [PMID: 35947637 DOI: 10.1073/pnas.2206610119] [Reference Citation Analysis]
2 Pertzov B, Shapira G, Abushkara S, Cohen S, Turjeman A, Kramer MR, Gurwitz D, Shomron N. Lower serum alpha 1 antitrypsin levels in patients with severe COVID-19 compared with patients hospitalized due to non-COVID-19 pneumonia. Infect Dis (Lond) 2022;:1-6. [PMID: 35975662 DOI: 10.1080/23744235.2022.2111464] [Reference Citation Analysis]
3 Abd HA, Kasim AA, Shareef LG. Serum levels of α1-antitrypsin, interleukin-1β and interleukin-6 in Iraqi COVID-19 patients: A cross-sectional study. F1000Res 2022;11:921. [DOI: 10.12688/f1000research.124473.1] [Reference Citation Analysis]
4 Philippe A, Puel M, Narjoz C, Gendron N, Durey-Dragon MA, Vedie B, Balduyck M, Chocron R, Hauw-Berlemont C, Sanchez O, Mirault T, Diehl JL, Smadja DM, Loriot MA. Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19. Biochimie 2022:S0300-9084(22)00188-2. [PMID: 35952950 DOI: 10.1016/j.biochi.2022.07.012] [Reference Citation Analysis]
5 Kayabolen A, Akcan U, Özturan D, Ulbegi-Polat H, Sahin GN, Pinarbasi-Degirmenci N, Bayraktar C, Soyler G, Sarayloo E, Nurtop E, Ozer B, Guney-Esken G, Barlas T, Yildirim IS, Dogan O, Karahuseyinoglu S, Lack NA, Kaya M, Albayrak C, Can F, Solaroglu I, Bagci-Onder T. Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo. Adv Sci (Weinh) 2022;:e2201294. [PMID: 35896894 DOI: 10.1002/advs.202201294] [Reference Citation Analysis]
6 García-Carmona S, Falfán-Valencia R, Verónica-Aguilar A, Buendía-Roldán I, Chávez-Galán L, Hernández-Zenteno RJ, Martínez-Morales A, Fricke-Galindo I, Alanis-Ponce J, Valencia-Pérez Rea D, Gutiérrez-Pérez IA, Zaragoza-García O, Nava-Quiroz KJ, Camarena A, Mejía M, Guzmán-Guzmán IP, Pérez-Rubio G. COVID-19 Survivor Patients Carrying the Rs35705950 Risk Allele in MUC5B Have Higher Plasma Levels of Mucin 5B. Curr Issues Mol Biol 2022;44:3283-90. [PMID: 35892712 DOI: 10.3390/cimb44080226] [Reference Citation Analysis]
7 Wettstein L, Knaff PM, Kersten C, Müller P, Weil T, Conzelmann C, Müller JA, Brückner M, Hoffmann M, Pöhlmann S, Schirmeister T, Landfester K, Münch J, Mailänder V. Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture. Commun Biol 2022;5:681. [PMID: 35804152 DOI: 10.1038/s42003-022-03613-4] [Reference Citation Analysis]
8 Nygren D, Mölstad U, Thulesius H, Hillman M, Broman LM, Tanash H, Landin-Olsson M, Rasmussen M, Thunander M. Low Prevalence of Mild Alpha-1-Antitrypsin Deficiency in Hospitalized COVID-19-Patients. Int J Gen Med 2022;15:5843-8. [PMID: 35789772 DOI: 10.2147/IJGM.S370434] [Reference Citation Analysis]
9 Köhnlein T, Wilkens M, Eydt K. [Impact of COVID-19 pandemic on information management and adherence to replacement therapy with AAT of patients with alpha-1 antitrypsin deficiency (AATM)]. Pneumologie 2022. [PMID: 35724679 DOI: 10.1055/a-1845-0160] [Reference Citation Analysis]
10 Rosendal E, Mihai IS, Becker M, Das D, Frängsmyr L, Persson BD, Rankin GD, Gröning R, Trygg J, Forsell M, Ankarklev J, Blomberg A, Henriksson J, Överby AK, Lenman A, Moscona A. Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections. mBio. [DOI: 10.1128/mbio.00892-22] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Dai J, Wang H, Liao Y, Tan L, Sun Y, Song C, Liu W, Qiu X, Ding C. Coronavirus Infection and Cholesterol Metabolism. Front Immunol 2022;13:791267. [DOI: 10.3389/fimmu.2022.791267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Bai X, Buckle AM, Vladar EK, Janoff EN, Khare R, Ordway D, Beckham D, Fornis LB, Majluf-Cruz A, Fugit RV, Freed BM, Kim S, Sandhaus RA, Chan ED. Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. Sci Rep 2022;12:5207. [PMID: 35338216 DOI: 10.1038/s41598-022-09133-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Thomas G, Couture F, Kwiatkowska A. The Path to Therapeutic Furin Inhibitors: From Yeast Pheromones to SARS-CoV-2. Int J Mol Sci 2022;23:3435. [PMID: 35408793 DOI: 10.3390/ijms23073435] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cheudjeu A. The SARS-CoV-2 Entry Inhibition Mechanisms of Serine Protease Inhibitors, OM-85, Heparin and Soluble HS Might Be Linked to HS Attachment Sites. Molecules 2022;27:1947. [DOI: 10.3390/molecules27061947] [Reference Citation Analysis]
15 Rani P, Kapoor B, Gulati M, Atanasov AG, Alzahrani Q, Gupta R. Antimicrobial peptides: A plausible approach for COVID-19 treatment. Expert Opin Drug Discov 2022;:1-15. [PMID: 35255763 DOI: 10.1080/17460441.2022.2050693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 O'Brien ME, Murray G, Gogoi D, Yusuf A, McCarthy C, Wormald MR, Casey M, Gabillard-Lefort C, McElvaney NG, Reeves EP. A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application. Int J Mol Sci 2022;23:2441. [PMID: 35269582 DOI: 10.3390/ijms23052441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Boraldi F, Lofaro FD, Cossarizza A, Quaglino D. The "Elastic Perspective" of SARS-CoV-2 Infection and the Role of Intrinsic and Extrinsic Factors. Int J Mol Sci 2022;23:1559. [PMID: 35163482 DOI: 10.3390/ijms23031559] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yang C, Zhao H, Tebbutt SJ. Leave no one behind: inclusion of alpha-1 antitrypsin deficiency patients in COVID-19 vaccine trials. Eur J Hum Genet 2022. [PMID: 35087186 DOI: 10.1038/s41431-022-01047-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Mantzourani C, Vasilakaki S, Gerogianni V, Kokotos G. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19. Expert Opinion on Drug Discovery. [DOI: 10.1080/17460441.2022.2029843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Fromme M, Schneider CV, Trautwein C, Brunetti-Pierri N, Strnad P. Alpha-1 antitrypsin deficiency: a re-surfacing adult liver disorder. J Hepatol 2021:S0168-8278(21)02227-3. [PMID: 34848258 DOI: 10.1016/j.jhep.2021.11.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
21 Vianello A, Guarnieri G, Braccioni F, Lococo S, Molena B, Cecchetto A, Giraudo C, Bertagna De Marchi L, Caminati M, Senna G. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med 2021. [PMID: 34783228 DOI: 10.1515/cclm-2021-1021] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Baristaite G, Gurwitz D. d-Galactose treatment increases ACE2, TMPRSS2, and FURIN and reduces SERPINA1 mRNA expression in A549 human lung epithelial cells. Drug Dev Res 2021. [PMID: 34677831 DOI: 10.1002/ddr.21891] [Reference Citation Analysis]
23 Yang Y, Yan G, Kong S, Wu M, Yang P, Cao W, Qiao L. GproDIA enables data-independent acquisition glycoproteomics with comprehensive statistical control. Nat Commun 2021;12:6073. [PMID: 34663801 DOI: 10.1038/s41467-021-26246-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
24 Dahal A, Sonju JJ, Kousoulas KG, Jois SD. Peptides and peptidomimetics as therapeutic agents for Covid-19. Pept Sci (Hoboken) 2021;:e24245. [PMID: 34901700 DOI: 10.1002/pep2.24245] [Reference Citation Analysis]
25 Lee WS, Yousefi M, Yan B, Yong CL, Ooi YS. Know your enemy and know yourself - the case of SARS-CoV-2 host factors. Curr Opin Virol 2021;50:159-70. [PMID: 34488003 DOI: 10.1016/j.coviro.2021.08.007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
26 Baggen J, Vanstreels E, Jansen S, Daelemans D. Cellular host factors for SARS-CoV-2 infection. Nat Microbiol 2021;6:1219-32. [PMID: 34471255 DOI: 10.1038/s41564-021-00958-0] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
27 Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW. SARS-CoV-2 Antiviral Therapy. Clin Microbiol Rev 2021;:e0010921. [PMID: 34319150 DOI: 10.1128/CMR.00109-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
28 Stevens CS, Oguntuyo KY, Lee B. Proteases and variants: context matters for SARS-CoV-2 entry assays. Curr Opin Virol 2021;50:49-58. [PMID: 34365113 DOI: 10.1016/j.coviro.2021.07.004] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
29 Schneider CV, Strnad P. SARS-CoV-2 infection in alpha1-antitrypsin deficiency. Respir Med 2021;184:106466. [PMID: 34010739 DOI: 10.1016/j.rmed.2021.106466] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
30 Jahrsdörfer B, Groß R, Seidel A, Wettstein L, Ludwig C, Schwarz T, Körper S, Rojewski M, Lotfi R, Weinstock C, Seifried E, Corman VM, Drosten C, Münch J, Schrezenmeier H. Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors. J Immunol 2021;206:2614-22. [PMID: 33980583 DOI: 10.4049/jimmunol.2100036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
31 Estey MP, Tahooni T, Nelson TN, Parker ML, Agbor TA, Yang HM, Jen R, Barakauskas VE, Lam GY, Matthews A, Mattman A. Is the diagnostic rate for the common subtypes of A1AT deficiency consistent across two Canadian Provinces? Clin Biochem 2021;95:84-8. [PMID: 33964271 DOI: 10.1016/j.clinbiochem.2021.05.002] [Reference Citation Analysis]
32 Fuentes-Prior P. Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection. J Biol Chem 2021;296:100135. [PMID: 33268377 DOI: 10.1074/jbc.REV120.015980] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]